Literature DB >> 29085510

Regulation of paclitaxel sensitivity in prostate cancer cells by PTEN/maspin signaling.

Yu Gan1, Qing Chen2, Yan Lei3.   

Abstract

Taxol is the first-line chemotherapeutic agent for patients with castration-resistant prostate cancer. However, the mechanism of the sensitivity of prostate cancer cells to Taxol treatment remains to be elucidated. In the present study, it was found that paclitaxel induced more apoptosis and maspin expression in phosphatase and tensin homolog (PTEN)-positive 22Rv1 cells than PTEN-negative LNCaP cells. Knockdown of PTEN in 22Rv1 cells resulted in increased resistance to paclitaxel and impaired the induction of maspin expression by paclitaxel. Overexpression of PTEN sensitized LNCaP cells to paclitaxel treatment and increased maspin induction by paclitaxel. Furthermore, knocking down maspin abrogated PTEN-induced paclitaxel sensitivity in LNCaP cells. PTEN/maspin signaling may be important for regulating the susceptibility to paclitaxel in prostate cancer.

Entities:  

Keywords:  PTEN; drug sensitivity; maspin; paclitaxel; prostate cancer cells

Year:  2017        PMID: 29085510      PMCID: PMC5649693          DOI: 10.3892/ol.2017.6793

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  25 in total

1.  Mechanisms of androgen-refractory prostate cancer.

Authors:  Jose D Debes; Donald J Tindall
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

2.  Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis.

Authors:  Ran Zhang; Naren L Banik; Swapan K Ray
Journal:  Brain Res       Date:  2008-09-04       Impact factor: 3.252

3.  Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.

Authors:  Sooyong Lee; Eui-Ju Choi; Changbae Jin; Dong-Hyun Kim
Journal:  Gynecol Oncol       Date:  2005-04       Impact factor: 5.482

4.  Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.

Authors:  Su-Hyeong Kim; Yong-Sung Juhnn; Yong-Sang Song
Journal:  Ann N Y Acad Sci       Date:  2007-01       Impact factor: 5.691

5.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells.

Authors:  Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager
Journal:  Science       Date:  1994-01-28       Impact factor: 47.728

6.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Maspin overexpression correlates with positive response to primary chemotherapy in ovarian cancer patients.

Authors:  Dagmara Klasa-Mazurkiewicz; Joanna Narkiewicz; Tomasz Milczek; Barbara Lipińska; Janusz Emerich
Journal:  Gynecol Oncol       Date:  2009-02-03       Impact factor: 5.482

Review 9.  Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms.

Authors:  Nadeem Bilani; Hisham Bahmad; Wassim Abou-Kheir
Journal:  Front Pharmacol       Date:  2017-03-21       Impact factor: 5.810

10.  Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.

Authors:  Zibin Jiang; Nabendu Pore; George J Cerniglia; Rosemarie Mick; Maria-Magdelena Georgescu; Eric J Bernhard; Stephen M Hahn; Anjali K Gupta; Amit Maity
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

View more
  5 in total

1.  SGO1 induces proliferation and metastasis of prostate cancer through AKT-mediated signaling pathway.

Authors:  Qi Chen; Xiang Wan; Yanbo Chen; Chong Liu; Meng Gu; Zhong Wang
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

Review 2.  Insights into Aptamer-Drug Delivery Systems against Prostate Cancer.

Authors:  Xueni Wang; Qian Zhou; Xiaoning Li; Xia Gan; Peng Liu; Xiaotao Feng; Gang Fang; Yonghong Liu
Journal:  Molecules       Date:  2022-05-26       Impact factor: 4.927

3.  HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation.

Authors:  Fengbiao Guo; Jinping Li; Yaozhi Qi; Jianqing Hou; Haibin Chen; Shi-Wen Jiang
Journal:  Cancer Cell Int       Date:  2020-05-12       Impact factor: 5.722

Review 4.  Mechanisms of Taxane Resistance.

Authors:  Sara M Maloney; Camden A Hoover; Lorena V Morejon-Lasso; Jenifer R Prosperi
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

5.  The overexpression of maspin increases the sensitivity of lung adenocarcinoma drug-resistant cells to docetaxel in vitro and in vivo.

Authors:  Qian Sun; Kai Zhang; Huan Li; Weiwei Chen; Leilei Liu; Guichun Huang; Qun Zhang; Jing Wang; Lu Lu; Longbang Chen; Rui Wang
Journal:  Ann Transl Med       Date:  2020-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.